Suboxone
Phase 3Small molecule
Merck & Co.Suboxone is one of 74 small molecule programs targeting Hepatitis C. It is currently in Phase 3.
2
Indications
10
Total Trials
1
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
306 competitors in Hepatitis C
#DrugCompanyPhaseTrials
1Daklinza
Bristol-Myers SquibbPhase 3
Zepatier
Merck & Co.Phase 3
Peginterferon Alfa-2
RochePhase 3
Lexapro
AbbViePhase 3
Victrelis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Pegylated Interferon
Merck & Co.Phase 3
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
TMC435
Johnson & JohnsonPhase 3
Zetia
OOrganon and Co
Phase 3
Ombitasvir/paritaprevir/ritonavir
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Telemedicine1 trial
Providing Suboxone and PrEP Using Telemedicine
Completed·—·N/A·NCT04521920·17 enrolled
Hepatitis C1 trial
Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP
Completed·—·N/A·NCT05108935·17 enrolled
Opioid Use Disorder1 trial
Opioid1 trial
Houston Emergency Opioid Engagement System
Enrolling by invitation·TThe University of Texas Health Science Center, Houston·Phase 4·NCT03396276·3,000 enrolled
5 more indications
Acceptability1 trial
Opiate Dependence1 trial
Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence
Completed·—·Phase 3·NCT02696096·21 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Suboxone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company